Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatocellular carcinoma

M Sherman1

  • 1Division of Gastroenterology, Toronto Hospital, Ontario, Canada.

The Gastroenterologist
|March 1, 1995
PubMed
Summary
This summary is machine-generated.

Hepatocellular carcinoma (HCC) is a common cancer with identifiable causes like hepatitis B/C. However, its pathogenesis and effective screening/treatment strategies remain uncertain, impacting patient survival.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors associated with Noninvasive ventilation compliance in patients with ALS/MND.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2021
Same author

Why, How, and When the Cytological Diagnosis of ASCUS Should Be Eliminated.

Journal of lower genital tract disease·2015
Same author

Metabolic syndrome-related hepatocellular carcinoma treated by volumetric modulated arc therapy.

Current oncology (Toronto, Ont.)·2014
Same author

Historical epidemiology of hepatitis C virus (HCV) in selected countries.

Journal of viral hepatitis·2014
Same author

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.

Journal of viral hepatitis·2014
Same author

Strategies to manage hepatitis C virus (HCV) disease burden.

Journal of viral hepatitis·2014
Same journal

Pseudomyxoma peritonei.

The Gastroenterologist·1998
Same journal

Update on obesity treatment.

The Gastroenterologist·1998
Same journal

Pathophysiology and treatment of hepatorenal syndrome.

The Gastroenterologist·1998
Same journal

Common pediatric esophageal disorders.

The Gastroenterologist·1998
Same journal

The technical aspects of biofeedback therapy for defecation disorders.

The Gastroenterologist·1998
Same journal

Magnetic resonance cholangiopancreatography: a new technique for evaluating the biliary tract and pancreatic duct.

The Gastroenterologist·1998
See all related articles

Area of Science:

  • Hepatology and Oncology
  • Gastroenterology
  • Cancer Research

Background:

  • Hepatocellular carcinoma (HCC) ranks among the top 10 globally, with incidence varying geographically.
  • Key etiological factors include chronic hepatitis B and C infections, alcoholic liver disease, hemochromatosis, and alpha-1-antitrypsin deficiency.
  • While causes are often identifiable, the precise pathogenesis, including the role of Aflatoxin B1 and viral-induced genetic changes, is uncertain.

Purpose of the Study:

  • To review the current understanding of hepatocellular carcinoma (HCC) epidemiology, pathogenesis, screening, and treatment.
  • To highlight the uncertainties in HCC pathogenesis and the limitations of current screening and therapeutic approaches.
  • To discuss the challenges in improving survival rates for patients with HCC.

Main Methods:

Related Experiment Videos

  • Literature review and synthesis of existing data on HCC.
  • Analysis of etiological factors, pathogenetic mechanisms, and genetic alterations.
  • Evaluation of current screening modalities (alphafetoprotein, ultrasonography) and therapeutic options (surgery, chemotherapy, embolization, radiotherapy, ablation).

Main Results:

  • Chronic hepatitis B and C are primary drivers of HCC globally.
  • Pathogenesis involves factors like Aflatoxin B1 and viral-induced necrosis/regeneration, with p53 mutations being a late event.
  • Screening lacks proven survival benefits due to limitations imposed by cirrhosis, recurrence rates, and underlying chronic liver disease.

Conclusions:

  • Despite advances, significant gaps remain in understanding HCC pathogenesis and improving patient outcomes.
  • Current screening methods identify small tumors but do not consistently enhance survival.
  • While surgery is preferred, most therapies are palliative, underscoring the need for more effective, evidence-based treatments and improved screening efficacy.